Resistance to PD1/PDL1 checkpoint inhibition

Jake S. O’Donnell; Georgina V. Long; Richard A Scolyer; Michele W.L. Teng; Mark J. Smyth

doi:10.1016/j.ctrv.2016.11.007

Related publications

Article2015

Response to anti-PD1/PDL1 therapy in patients with metastatic desmoplastic melanoma.

Zeynep Eroglu, Dae Won Kim, Douglas B. Johnson, Alain P. Algazi, Rodrigo Ramella Munhoz, Elizabeth Liniker, Ben L. Kong, Neharika Khurana, Bartosz Chmielowski, Jeffrey A. Sosman, Richard A Scolyer, Matteo S. Carlino, Michael A. Postow, Wen‐Jen Hwu, Georgina V. Long, Antoni Ribas

Article2020

Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

Andy Karabajakian, Thibaut Garrivier, Carole Crozes, Nicolas Gadot, Jean Yves Blay, F. Bérard, Philippe Céruse, Philippe Zrounba, Pierre Saintigny, Charles Mastier, Jérôme Fayette

Article2023

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond

Mina Fazel, Armelle Dufresne, Hélène Vanacker, Waïsse Waïssi, Jean Yves Blay, Mehdi Brahmi

Corrigendum2022

Addendum: Hyperprogression and impact of tumor growth kinetics after PD1/PDL1 inhibition in head and neck squamous cell carcinoma

Andy Karabajakian, Thibaut Garrivier, Carole Crozes, Nicolas Gadot, Jean Yves Blay, F. Bérard, Philippe Céruse, Philippe Zrounba, Pierre Saintigny, Charles Mastier, Jérôme Fayette

Article2021

Immune checkpoint inhibition in classical hodgkin lymphoma

Parmida Sadat Pezeshki, Mahsa Eskian, Michael R Hamblin, Nima Rezaei